FGF23 and cystic fibrosis: To further elucidate the signaling pathway involved leading to IL-8 secretion, we treated CF-HBECs with TGF-β and FGF23 and either LY2157299, SB203580, or AZD4547, a FGFR1–3 inhibitor.